Mr. Eduardo G.
Bezerra named EVP, Chief Financial Officer
Mr. Todd Kingma
to retire after 19 years of service; Ms. Kyle L. Hanson to be named EVP, General Counsel
and Corporate Secretary
DUBLIN, May 11, 2022
/PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading
provider of Consumer Self-Care products, today made two
announcements regarding the planned succession of its executive
leadership team. Mr. Eduardo Bezerra
has been named Executive Vice President and Chief Financial
Officer, effective May 16, 2022,
succeeding Mr. Ray Silcock, who
previously announced his intent to retire. Mr. Silcock will serve
in an advisory capacity until his retirement on July 15, 2022. The Company also announced the
planned retirement of Mr. Todd
Kingma, Executive Vice President, General Counsel and
Corporate Secretary. Ms. Kyle Hanson
has been named Executive Vice President, General Counsel and
Corporate Secretary effective June 1,
2022, at which point Mr. Kingma will serve in an advisory
capacity until his retirement on August 31,
2022.
Perrigo President and CEO, Murray S.
Kessler commented, "The appointments of Kyle and Eduardo are a
key part of the next phase of Perrigo's consumer self-care
strategy. They represent the next generation of Perrigo leaders who
will help 'Optimize and Accelerate' the newly transformed
organization. They both have the passion and experience that embody
'The Perrigo Advantage', and I am confident that their diverse
perspectives and deep experience will contribute to Perrigo's
success. By focusing on our supply chain reinvention, successfully
integrating HRA Pharma, growing gross margins, driving innovation
and continually improving our organization and culture, the path
ahead for Perrigo is clear, and we have the leadership to make it
happen."
Mr. Eduardo Bezerra Named Chief Financial Officer
Bezerra joins Perrigo from Fresh Del Monte Produce, Inc.
(NYSE: FDP), where he served as Senior Vice President and Chief
Financial Officer. He previously served in multiple finance, as
well commercial and strategy positions with increasing
responsibility at Monsanto Company for over 20 years, before the
company was acquired by Bayer AG, when he took the lead on all
finance-related integration matters.
Kessler continued, "We are excited to have Eduardo join Perrigo
with his extensive experience leading finance functions and growing
margins at fast-moving consumer goods companies. In addition, he
previously implemented global finance shared services structures,
managed large integration processes, in addition to his deep
international experience, having led teams across all 5
continents. I look forward to closely working with Eduardo on
driving operational excellence through our Supply Chain Reinvention
program and strengthening our balance sheet through working capital
improvements and value-driving capital allocation."
Mr. Bezerra said, "I am excited to join Perrigo and help the
company profitably and sustainably turn its consumer self-care
vision into a reality. It is a privilege to join Perrigo's
executive team and to partner with its talented finance
organization, to advance the Company's powerful strategy while
building value for shareholders."
Mr. Todd Kingma Announces Retirement
Kessler said, "On behalf of the Board of Directors and
leadership team, I would like to thank Todd for his valued
leadership and significant contributions over his 19 years at
Perrigo. Todd had considered retiring sooner, but at my and the
Board's request, he agreed to stay until the major uncertainties
challenging the company were resolved. And I am proud that he did
just that. Todd has been a trusted voice to me and the Board, and a
key contributor to the senior leadership of Perrigo, helping guide
the Company through many successes, including, most recently, our
transformation to a leading self-care company and the resolution of
the Irish Tax assessment. I am grateful for Todd's many
contributions to Perrigo and am delighted to see him retire as the
winner he is. I also appreciate that he has agreed to stay on as an
advisor until the end of the summer to ensure a seamless transition
with our new General Counsel."
Commenting on his planned retirement, Mr. Kingma noted, "I
am extremely grateful for my career at Perrigo. It has been a
privilege to serve and work closely with the many incredible people
at Perrigo. I am pleased that Kyle will be joining Perrigo and
believe that she is the right person to lead Perrigo's talented
Legal and Compliance team. I look forward to working closely
with Kyle over the coming months to ensure a seamless
transition."
Ms. Kyle Hanson Named General Counsel and Secretary
Ms. Hanson is a highly skilled lawyer, with nearly 25 years of
experience as counsel for consumer-focused companies. She spent the
last four years at Wolverine Worldwide, Inc. (NYSE: WWW), where she
served as Senior Vice President, General Counsel and Secretary.
Prior to Wolverine, Ms. Hanson served for 20 years in various roles
of increasing responsibility, including as General Counsel, at The
Buckle (NYSE: BKE).
"As part of the next generation of Perrigo leaders, Kyle's
extensive experience in the consumer industry will provide valuable
perspective and insight to the Company," said Kessler. "Kyle not
only brings consumer expertise, passion and strong judgement, she
is also an experienced litigator that will help Perrigo further
reduce uncertainty."
Ms. Hanson commented, "I am honored for the opportunity to join
such a great company at a perfect time in its storied history. I
look forward to a smooth transition with Todd and am excited to
help advance Perrigo's purposeful self-care vision."
Search Advisor
Mattson and Company, a select board advisory and executive
search firm that specializes in senior executive talent selection
and effective board governance, completed the engagement for
Perrigo that resulted in the hiring of Mr. Bezerra as Chief
Financial Officer and Ms. Hanson as General Counsel.
About Perrigo
Perrigo Company plc (NYSE: PRGO) is a leading provider of
Quality, Affordable Self-Care Products and over-the-counter (OTC)
health and wellness solutions that enhance individual well-being by
empowering consumers to proactively prevent or treat conditions
that can be self-managed. Led by its consumer self-care strategy,
Perrigo is the largest store brand OTC player in the U.S. in the
categories in which it competes through more than 9,000 SKUs under
customer 'own brand' labels. Additionally, Perrigo is a Top 10 OTC
company by revenue in Europe,
where it markets more than 200 branded OTC products throughout 28
countries. Visit Perrigo online at www.perrigo.com.
About Mattson and Company
With top executive search professionals in NYC, Chicago, Indianapolis, Atlanta, Manchester, Short Hills and Palm Beach, Mattson and Company is a highly
specialized boutique consulting firm with experienced consultants
who are trusted advisors to Boards and Chief Executive
Officers. Founded in 2014 by Gayle
Mattson, the firm's partners offer a wealth of knowledge in
successfully implementing solutions to critical issues facing
Boards and C-Suite executives with select clients to create close
and unconflicted relationships. www.mattsonandco.com
Forward-Looking Statements
Certain statements in this press release are "forward-looking
statements." These statements relate to future events or the
Company's future financial performance and involve known and
unknown risks, uncertainties and other factors that may cause the
actual results, levels of activity, performance or achievements of
the Company or its industry to be materially different from those
expressed or implied by any forward-looking statements. In some
cases, forward-looking statements can be identified by terminology
such as "may," "will," "could," "would," "should," "expect,"
"forecast," "plan," "anticipate," "intend," "believe," "estimate,"
"predict," "potential" or the negative of those terms or other
comparable terminology. The Company has based these forward-looking
statements on its current expectations, assumptions, estimates and
projections. While the Company believes these expectations,
assumptions, estimates and projections are reasonable, such
forward-looking statements are only predictions and involve known
and unknown risks and uncertainties, many of which are beyond the
Company's control, including: the effect of the coronavirus
(COVID-19) pandemic and its variants and associated supply chain
impacts on the Company's business; general economic, credit, and
market conditions; the impact of the war in Ukraine and any escalation thereof, including
the effects of economic and political sanctions imposed by
the United States, United Kingdom, European Union, and other
countries related thereto; the outbreak or escalation of conflict
in other regions where we do business; future impairment charges;
customer acceptance of new products; competition from other
industry participants, some of whom have greater marketing
resources or larger market shares in certain product categories
than the Company does; pricing pressures from customers and
consumers; resolution of uncertain tax positions, including the
Company's appeal of the draft and final Notices of Proposed
Assessment ("NOPAs") issued by the U.S. Internal Revenue Service
and the impact that an adverse result in any such proceedings would
have on operating results, cash flows, and liquidity; pending and
potential third-party claims and litigation, including litigation
relating to the Company's restatement of previously-filed financial
information and litigation relating to uncertain tax positions,
including the NOPAs; potential impacts of ongoing or future
government investigations and regulatory initiatives; potential
costs and reputational impact of product recalls or sales halts;
the impact of tax reform legislation and/or changes in
healthcare policy; the timing, amount and cost of any share
repurchases; fluctuations in currency exchange rates and interest
rates; the Company's ability to achieve the benefits expected from
the sale of its Rx business and the risk that potential costs or
liabilities incurred or retained in connection with that
transaction may exceed the Company's estimates or adversely affect
the Company's business or operations; the Company's ability to
achieve the benefits expected from the acquisition of Héra SAS
("HRA Pharma") and the risks that the Company's synergy estimates
are inaccurate or that the Company faces higher than anticipated
integration or other costs in connection with the acquisition;
risks associated with the integration of HRA Pharma, including the
risk that growth rates are adversely affected by any delay in the
integration of sales and distribution networks;; the consummation
and success of other announced and unannounced acquisitions or
dispositions, and the Company's ability to realize the desired
benefits thereof; and the Company's ability to execute and achieve
the desired benefits of announced cost-reduction efforts and
strategic and other initiatives. An adverse result with respect to
the Company's appeal of any material outstanding tax assessments or
pending litigation, including securities or drug pricing matters,
could ultimately require the use of corporate assets to pay such
assessments, damages from third-party claims, and related interest
and/or penalties, and any such use of corporate assets would limit
the assets available for other corporate purposes. These and
other important factors, including those discussed under "Risk
Factors" in the Company's Form 10-K for the year ended December 31, 2021, as well as the Company's
subsequent filings with the United States Securities and Exchange
Commission, may cause actual results, performance or achievements
to differ materially from those expressed or implied by these
forward-looking statements. The forward-looking statements in this
press release are made only as of the date hereof, and unless
otherwise required by applicable securities laws, the Company
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/perrigo-announces-planned-leadership-succession-301544858.html
SOURCE Perrigo Company plc